NCT00503360View on ClinicalTrials.gov

Tolerability, Safety and Efficacy of SAD448 in Subjects With Ocular Hypertension

PHASE1CompletedINTERVENTIONAL

Enrollment

80

Participants

Timeline

Start Date

April 30, 2007

Conditions

Ocular Hypertension

Interventions

DRUG

SAD448

Trial Locations (1)

Unknown

Novartis Investigative site, Sydney, Australia, Sydney

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Novartis

INDUSTRY